文献速递脊柱关节炎

银屑病关节炎的精准医学:如何选择靶向治疗?

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
PubMed 文献 · Lancet Rheumatol · 2019-08-28

银屑病关节炎(PsA)是一种与银屑病相关的异质性炎性关节炎,可累及外周关节、脊柱、肌腱、皮肤和指甲。靶向治疗选择迅速增多,但接受治疗者中达到最佳治疗目标者通常不足一半,且缺乏指导个体化选药的证据。本文综述近期数据,指出PsA精准医学研究仍处初步阶段,未来需结合详细免疫表型分析与复杂统计分析来推动个体化治疗。

要点

  • PsA表现异质,靶向治疗后达到最佳目标者通常不足一半。
  • 目前选药主要依据活跃临床领域、医生熟悉度和费用。
  • 精准医学在PsA仍处初步阶段,需免疫表型与统计分析结合。

核心结论

  • PsA靶向治疗应答不足普遍,精准医学研究尚处初步阶段,未来需免疫表型与复杂统计分析结合以推动个体化选药。

研究设计与样本

  • 本文为综述,回顾近期关于PsA及其他炎性关节炎中个体化或精准医学潜力的数据。

主要发现

  • 接受靶向治疗的PsA患者中达到最佳治疗目标者通常不足一半。
  • 许多患者对二线或三线生物制剂有应答,但指导个体选药的证据很少。
  • 目前治疗选择由活跃临床疾病领域、医生对现有治疗的熟悉程度和费用驱动。

临床怎么用

  • 当前PsA靶向治疗选择可依据活跃临床疾病领域、医生熟悉度和费用进行决策。
  • 精准医学方法尚未成熟,暂不能常规用于个体化选药。

局限性

  • PsA精准医学相关研究仍处于初步阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis. Patients manifest variable presentations with potential involvement of peripheral joints, spine, tendons, skin, and nails. There has been a rapid expansion in targeted treatment options for patients with PsA, but typically less than half of those who receive therapy achieve optimal treatment targets. Many patients respond to second-line or third-line biological therapies, but little evidence exists to guide the choice of therapeutics for each individual. At present, choice of therapy is driven by active clinical disease domains, clinician familiarity with existing treatments, and cost. Here, we review recent data that highlight the potential for personalised, or precision, medicine in PsA and other forms of inflammatory arthritis, noting that this research is still at a preliminary stage. In the future, a combination of detailed immunophenotyping and sophisticated statistical analyses should help to facilitate a personalised medicine approach in PsA, following examples from other clinical areas, such as oncology. This change in approach to the treatment of PsA has the potential to maximise outcomes for patients and to provide optimal therapies without delay.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Al-Mossawi H, Taams LS, Goodyear CS, et al. Precision medicine in psoriatic arthritis: how should we select targeted therapies? Lancet Rheumatol. 2019. PMID: 38229362. doi:10.1016/S2665-9913(19)30008-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。